Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

By Nikita Chaurasia  Date: 2020-05-18

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial for assessing a possible coronavirus vaccine.

The Prime Minister of Canada, Justin Trudeau made this announcement on Saturday during his daily address to the nation.

Trudeau stated that research and development require time, and should be done right. However, despite the fact, this is a good news. The National Research Council would be working closely alongside the manufacturers, so in case the clinical trials are a success, the coronavirus vaccine can be manufactured and distributed at scale.

The clinical trials have been authorized by Health Canada and would be carried out at the CCfV (Canadian Centre for Vaccinology) at the Dalhousie University, Halifax. The CCfV team comprises 45 people working together on a potential vaccine candidate from CanSino Biologics.

Health Canada, while speaking about the trial, stated that the approval for going ahead with the trial was done after a careful review of the submitted trial application, which fulfilled the necessary quality and safety requirements.

Researchers stated that approximately 600 participants would be required to commence the clinical study.

Scott Halperin, CCfV Director and professor of immunology, pediatrics, and microbiology at Dalhousie University, stated that they would be further building upon the trials that have already started in China.   

Halperin further added that a vaccine strain known as Ad5-nCoV utilizes another virus which is modified to not cause infection within humans. It expresses a COVID-19 antigen called spike protein on its surface. If the trial participants create antibodies to tackle this antigen, then the formulation might prove helpful against the coronavirus.

Halperin hopes that the clinical trials would start in the coming two weeks once the team receives its approval from the ethics board.

Less than 100 participants of different ages would be tested in Phase 1. Phase 2 is expected to have more than 500 participants ranging between 18 to 85 years of age.

 

Source credit: https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

U.K. might ease lockdown restrictions following drop in COVID-19 cases

U.K. might ease lockdown restrictions following drop in COVID-19 cases

By Nikita Chaurasia

British Prime Minister Boris Johnson is reportedly planning to further ease lockdown restrictions in the United Kingdom. This announcement comes after Britain witnessed a drop in the daily death toll and case count, primarily due to rapid vaccination...

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

Maruti Suzuki India prolongs maintenance shutdown over COVID-19 fears

By Nikita Chaurasia

Maruti Suzuki India Limited has reportedly extended its maintenance shutdown from May 9th to May 16th amidst rising COVID-19 cases across the country. However, it is difficult to ascertain whether the intention behind the extended shutdown is to guar...

Amazon sets tougher rules for its delivery service partners’ employees

Amazon sets tougher rules for its delivery service partners’ employees

By Nikita Chaurasia

Amazon is known for closely managing its staff and contractors, and it also seeks to control the employees of the companies in which it works. Reportedly, the company has updated its policies for Amazon’s delivery partners wherein it lays out d...

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

BMW, Ford lead Solid Power’s USD 130 million Series B funding round

By Nikita Chaurasia

Solid Power Inc., a leading U.S-based producer of solid-state batteries has reportedly secured USD 130 million in the Series B funding round led by renowned car makers namely Ford Motor Company and BMW Group.  These funds will be used to develo...

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to...